The application value of flupentixol-melitracen after percutaneous coronary intervention
10.3760/cma.j.issn.1008-6706.2016.06.022
- VernacularTitle:氟哌噻吨美利曲辛在冠心病介入术后的应用价值
- Author:
Xiaomin WANG
- Publication Type:Journal Article
- Keywords:
Coronary artery disease;
Flupentixol melitracen
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(6):880-883
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the short and long-term effects of flupentixol-melitracen after percu-taneous coronary intervention( PCI) .Methods 86 patients with coronary heart disease who would be given PCI were randomly divided into 43 cases of the study group and 43 cases of the control group.The control group was given conventional treatment after surgery, the study group was given flupentixol -melitracen on the basis of the control group.After one course,the mental status changes and short-term effect were observed.All the patients had been follow-up for 1 year to observe the occurrence of cardiovascular events.Results After one course,the HAMA and HAMD in the study group and the control group were (7.46 ±2.53) points and (15.74 ±3.16) points,(8.03 ± 1.97)points and (16.42 ±3.67)points respectively,which in the study group were lower than the control group (t=13.413,13.208, all P <0.01 ) .The total effective rate of the study group was 97.67%, which was higher than 81.40%of the control group (χ2 =6.081,P<0.05).During follow-up,the incidence rate of adverse cardiovascular events in the study group was 6.67%,which was lower than 42.86%of the control group (χ2 =9.564,P<0.05). Conclusion The flupentixol-melitracen can effectively improve anxiety and depression, improve the recent thera-peutic effect of PCI,reduce the incidence of cardiovascular events,which worthy of promotion after PCI.
